SLQT — SelectQuote, Inc.

Summary of SelectQuote (SLQT) Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $431 million, a 6% increase year-over-year.
• Adjusted EBITDA: $45 million, an 18% growth year-over-year. Excluding a favorable $14 million adjustment related to commissions receivable, the EBITDA margin would have been 7%.
• Senior Segment Revenue: $183 million, up 8% year-over-year, with an adjusted EBITDA of $59 million (26% margin).
• Healthcare Services Revenue: $199 million, up 5% year-over-year, with adjusted EBITDA of $5 million.
• Life Insurance Revenue: $48 million, a 4% increase year-over-year, generating $6 million in adjusted EBITDA.

2. Strategic Updates and Business Highlights

• SelectQuote Local Initiative: A new program aimed at helping underserved communities by allowing local healthcare providers to utilize SelectQuote's marketing and technology capabilities through a franchise model.
• Operational Efficiency: Improved agent productivity and marketing efficiency in the Senior segment, with a 1% increase in policies per agent and a 14% reduction in marketing spend per approved policy compared to two years ago.
• SelectRx Growth: Continued member onboarding with a 64% increase in prescriptions shipped compared to two years ago, and ongoing improvements in operational efficiency at the new Kansas City distribution facility.

3. Forward Guidance and Outlook

• Fiscal 2026 Guidance: Revenue expected between $1.61 billion and $1.71 billion, with adjusted EBITDA between $90 million and $100 million.
• Fiscal 2027 Outlook: Management is optimistic about accelerating cash flow generation and improving profitability, particularly in the Healthcare Services segment.

4. Bad News, Challenges, or Points of Concern

• Healthcare Services Headwinds: Revenue impacted by the Inflation Reduction Act, which affected reimbursement rates, although the overall EBITDA impact was minor.
• Market Volatility: The Medicare Advantage environment remains mixed, with potential challenges in approval rates and reimbursement trends.
• Equity Valuation Disconnect: Management expressed concern over the significant gap between the perceived value of the company’s cash flows and its market capitalization, which is below $200 million despite nearly $1 billion in commissions receivable.

5. Notable Q&A Insights

• PBM Reimbursement Environment: Management indicated that the PBM reimbursement environment has stabilized, with a multi-year agreement secured with their largest PBM partner.
• Cash Flow Dynamics: Management highlighted ongoing improvements in cash flow generation and operational efficiencies, particularly in the SelectRx segment, with expectations to reach a $40 million to $50 million EBITDA run rate soon.
• Future LTV Calculations: The lifetime value (LTV) of customers may improve with increased stability in the Medicare environment, which has been disrupted in recent years.
• Market Trends: There are no significant changes in marketing spend from national carriers, and the company remains confident in its ability to navigate quieter periods effectively.

Overall, SelectQuote demonstrated strong financial performance in Q3 2026, with strategic initiatives aimed at enhancing growth and profitability, despite facing some industry headwinds and challenges related to market valuation.